PwC Corporate Finance advises Lonza on the acquisition of Micro-Macinazione

A team of PwC Switzerland led by Martin Frey, Partner Corporate Finance/M&A, acted as lead advisor to Lonza Group AG (“Lonza”), a Swiss leading supplier to the pharmaceutical, biotech and specialty ingredients markets. Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 50 major manufacturing and R&D facilities and nearly 14,000 full-time employees worldwide.

With over 45 years of experience, Micro-Macinazione S.A. is a leading provider of micronization services and equipment for the Pharmaceutical & Fine Chemical industry. The company was acquired in 2012 by Cross Equity Partners, a Swiss Private Equity fund active in the development of mid-sized companies in Switzerland, Germany and Austria.

Acquiring Micro-Macinazione was strategic for Lonza as it provides micronization technology and expertise that complements its existing US capabilities and provides additional capacity to support its growth.
Thanks to its close relationships with both Cross Equity and Lonza, PwC Corporate Finance team was able to bring both parties together in the negotiation and ensure a smooth and quick deal execution.